Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Integrative and Regenerative Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1510080

Solute carrier (SLC) proteins caused substances dysregulation in metabolic diseases and the potential in clinical application

Provisionally accepted
jiangxia Du jiangxia Du 1Minhui Shen Minhui Shen 2Jiajia Chen Jiajia Chen 2Hao Yan Hao Yan 2Zhifei Xu Zhifei Xu 2Xiaochun Yang Xiaochun Yang 2Bo Yang Bo Yang 3,4Peihua Luo Peihua Luo 2,5Kefeng Ding Kefeng Ding 1Yuhuai Hu Yuhuai Hu 6*Qiaojun He Qiaojun He 1,2,4,5*
  • 1 Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Jiangsu Province, China
  • 2 Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang Province, China
  • 3 Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang Province, China
  • 4 School of Medicine, Hangzhou City University, Hangzhou, China
  • 5 Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, Jiangsu Province, China
  • 6 Yuhong Pharmaceutical Technology Co. Ltd, Hangzhou, China

The final, formatted version of the article will be published soon.

    Carbohydrates, lipids, bile acids, various inorganic salt ions and organic acids are the main nutrients or indispensable components of the human body. Dysregulation in the processes of absorption, transport, metabolism, and excretion of these metabolites can lead to the onset of severe metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, gout and hyperbilirubinemia. As the second largest membrane receptor supergroup, several major families in the solute carrier (SLC) supergroup have been found to play key roles in the transport of substances such as carbohydrates, lipids, urate, bile acids, monocarboxylates and zinc ions. Based on common metabolic dysregulation and related metabolic substances, we explored the relationship between several major families of SLC supergroup and metabolic diseases, providing examples of drugs targeting SLC proteins that have been approved or are currently in clinical/preclinical research as well as SLC-related diagnostic techniques that are in clinical use or under investigation. By highlighting these connections, we aim to provide insights that may contribute to the development of improved treatment strategies and targeted therapies for metabolic disorders.

    Keywords: SLC, metabolic disease, transport substrate, transport dysregulation, therapeutic targets

    Received: 12 Oct 2024; Accepted: 20 Dec 2024.

    Copyright: © 2024 Du, Shen, Chen, Yan, Xu, Yang, Yang, Luo, Ding, Hu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yuhuai Hu, Yuhong Pharmaceutical Technology Co. Ltd, Hangzhou, China
    Qiaojun He, Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.